DDInter53 DDInter1752
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Alpelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Alpelisib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Alpelisib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Alpelisib may lead to a major life threatening interaction when taken with Edoxaban